

---

---

**Wen-Chun Hung, Ph.D.**

National Institute of Cancer Research

National Health Research Institutes

35, Keyan Road, Zhunan Town, Miaoli County 350401, Taiwan, ROC

Phone No.: 037206166 ext. 31020

Fax No.: 037581891

E-mail: [hung1228@nhri.edu.tw](mailto:hung1228@nhri.edu.tw)

Web: [https://nicr.nhri.edu.tw/pi/hungwc\\_cv/](https://nicr.nhri.edu.tw/pi/hungwc_cv/)

---

---

**Education**

- |           |  |
|-----------|--|
| 1981-1985 | BS, School of Technology for Medical Science, Kaohsiung Medical University |
| 1985-1987 | Master, Institute of Neuroscience, Yang-Ming Medical University            |
| 1990-1994 | PhD, Institute of Medicine, Kaohsiung Medical University                   |

**Research and Professional Positions Held in Chronological Sequence**

- |                 |   |
|-----------------|---|
| 1999-2004       | Professor, School of Technology for Medical Sciences, Kaohsiung Medical University, Kaohsiung, Taiwan                       |
| 2000-2001       | Chair, Division of Registration and Curriculum, Office of Academic Affairs, Kaohsiung Medical University, Kaohsiung, Taiwan |
| 2004-2008       | Director and Distinguished Professor, Institute of Biomedical Sciences, National Sun Yat-Sen University                     |
| 2008-2011       | Dean and Xi-Wan Chair Professor, College of Science, National Sun Yat-Sen University  |
| 2010-2011       | Chair, Domain of Microbiology, Immunology and Medical Technology, National Science Council, Taiwan, Republic of China       |
| 2011/06-2018/10 | Deputy Director, National Institute of Cancer Research, National Health Research Institutes                                 |
| 2018/12-2021/07 | Vice President and Distinguished Professor, Kaohsiung Medical University  |
| 2021/08-2022/08 | Director, Research Planning and Development, National Health Research Institutes  |
| 2022/01~        | Distinguished Investigator, National Institute of Cancer Research, National Health Research Institutes                      |
| 2023/02~        | Secretary General, National Health Research Institutes  |
| 2023/09-2024/07 | Acting Director, National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes             |
| 2023/05~        | Boards of Director, The Chinese Society of Cell and Molecular Biology   |

**Research Interests**

Cancer Biology, Pancreatic Cancer GEM model, Lymphangiogenesis and Tumor Metastasis, Anti-Cancer Drug Development

## Major Honors and Awards

2003	The Outstanding Research Award, National Science Council, ROC
2004	Dr. Chien-Tien Hsu's Outstanding Cancer Research Award, The Chinese Oncology Society, ROC
2004-2008	Distinguished Research Professor, National Sun Yat-Sen University, Taiwan, ROC
2005	The 1st Yung Shin Lee Tian-De Medical and Pharmaceutical Science and Technology Awards-Young Scientist Research Scholarship, ROC
2009-2011	Xi-Wan Chair Professor, National Sun Yat-Sen University, Taiwan, ROC
2010-2011	Chair, Domain of Microbiology, Immunology and Medical Technology, National Science Council, Taiwan, ROC
2020	Outstanding Research Award for Memory Lecture of Pin-Wen Lin, The 13th International Pancreatic Cancer Conference, ROC
2021-2024	World's Top 2% Scientists, Stanford University, USA
2022	Distinguished Investigator, National Institute of Cancer Research, National Health Research Institutes, ROC
2024	Dr. Tung Ta-Cheng's Basic Cancer Research Award, Taiwan Oncology Society, ROC
2024	The 21th National Innovation Award: University-Institute Innovation Award, Taiwan, ROC

## Representative Works (2023~) (\*corresponding author)

1. TL Kuo, KH Cheng, LT Chen, **WC Hung\***. (2023, Jan) ARID1A loss in pancreas leads to islet developmental defect and metabolic disturbance. *iScience*. 26(1):105881. (IF=5.8, MULTIDISCIPLINARY SCIENCES, RANK=15/73, Q1)
2. Hsu SH, **Hung WC\***. (2023, Feb) Protein arginine methyltransferase 3: A crucial regulator in metabolic reprogramming and gene expression in cancers. *Cancer Letters*. 554:216008. (IF=9.7, ONCOLOGY, RANK=34/241, Q1)
3. SH Hsu, YL Tsai, YT Wang, CH Shen, YH Hung, LT Chen, **WC Hung\***. (2024, Mar) RNF43 Inactivation Enhances the B-RAF/MEK Signaling and Creates a Combinatory Therapeutic Target in Cancer Cells. *Advanced Science*. 11(12):e2304820. (IF=15.1, CHEMISTRY, MULTIDISCIPLINARY, RANK=16/178, Q1)
4. Kuo TL, Hou YC, Shan YS, Chen LT, **Hung WC\***. (2025, Jul) Arid1a deficiency sensitises pancreatic cancer to fatty acid synthase inhibition. *Clin Transl Med*. 15(7):e70394.
5. CT Liu, YY Su, NJ Chiang, CF Li, YC Ma, KC Chang, YH Hung, **WC Hung\***, LT Chen\*. (2026, Feb) Mutant Isocitrate dehydrogenase 1 sensitizes intrahepatic cholangiocarcinoma cells to MDM2 inhibitors. *Cancer Res Commun*. doi: 10.1158/2767-9764.CRC-25-0591. Online ahead of print.